Aktiesnakken — November 2010
-
We are investing an increasing amount of our costbase... vi har tidl. sagt at omkring 25% af RD går til Merck... men svært at sige specifikt
-
hvad der er merck og hvad der ikke er merck-relateret
-
det er omk. relateret til forskellige interne ting... herunder preparation for fda inspections.
-
Long term guidance forventer vi stadig at kunne gi ved årsregnskab 2010.
-
Det var det... en hurtig omgang ift. normalt.
-
STORT tak til coller for fornem live rapportering fra CC
-
no problem... Men det er lidt svært at få det hele med i detaljer når de vælter spgm ud på stribe
-
interessante perspektiver med deres nye pen. kan det alene hæve indtjening med 10-15% af den 200 mio store oms?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind